Sonoma Pharmaceuticals Inc.
SNOA | NASDAQ
$1.26
+$0.01 (+0.80%)
Sep 22, 2026, 12:05 PM ET · Market open
Fiscal Year Period Ending | FY 2026 Mar 30, 2026 | FY 2025 Mar 30, 2025 | FY 2024 Mar 30, 2024 | FY 2023 Mar 30, 2023 | FY 2022 Mar 30, 2022 | FY 2021 Mar 30, 2021 |
|---|---|---|---|---|---|---|
Revenue | 19.53M | 14.29M | 12.74M | 13.27M | 12.63M | 18.63M |
Cost of Revenue | 12.11M | 8.82M | 7.99M | 8.8M | 8.64M | 12.07M |
Gross Profit | 7.42M | 5.47M | 4.75M | 4.48M | 3.99M | 6.56M |
Operating Income | -2.46M | -3.71M | -4.7M | -4.57M | -5.89M | -3.45M |
Interest Income | n/a | n/a | n/a | 16K | n/a | 16K |
Pretax Income | -3.42M | -2.91M | -5.03M | -5.18M | -5.42M | -3.9M |
Net Income | -3.18M | -3.46M | -4.84M | -5.15M | -5.09M | -3.95M |
Selling & General & Admin | 7.61M | 7.36M | 7.58M | 8.84M | 9.76M | 9.45M |
Research & Development | 2.27M | 1.81M | 1.87M | 207K | 125K | 555K |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 9.88M | 9.18M | 9.45M | 9.05M | 9.88M | 10.01M |
Interest Expense | n/a | n/a | n/a | n/a | 10K | 12K |
Selling & Marketing Expenses | n/a | 190K | n/a | n/a | n/a | n/a |
Cost & Expenses | 21.99M | 18M | 17.44M | 17.84M | 18.52M | 22.08M |
Income Tax Expense | -244K | 550K | -196K | -33K | -332K | 713K |
Shares Outstanding (Basic) | 1.68M | 1.24M | 909K | 339.4K | 265.3K | 199.6K |
Shares Outstanding (Diluted) | 1.68M | 1.24M | 909K | 339.4K | 265.3K | 199.6K |
EPS (Basic) | -1.89 | -2.79 | -5.32 | -15.18 | -19.17 | -23.65 |
EPS (Diluted) | -1.89 | -2.79 | -5.32 | -15.18 | -19.17 | -23.65 |
EBITDA | -2.32M | -2.77M | -4.86M | -5.06M | -5.22M | -3.22M |
EBIT | -2.46M | -2.91M | -5.03M | -5.18M | -5.41M | -3.45M |
Depreciation & Amortization | 139K | 138K | 176K | 125K | 186K | 227K |
Add to Watchlist
Select watchlists to add or remove SNOA